Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

Stanley R. Kay, Abraham Fiszbein, Lewis A. Opler · Schizophrenia Bulletin · 1987 · 21.4K citations · Full text

Social Sciences, Psychiatry, Psychology +17

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

Kevin D. Burris, Thaddeus F. Molski, Cen Xu et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 922 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

Steven G. Potkin, Anutosh Ranjan Saha, Mary J. Kujawa et al. · Archives of General Psychiatry · 2003 · 593 citations

Medicine, Pharmacology, Pharmacotherapy +16

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

Shaun Jordan, Vuk Koprivica, Ruoyan Chen et al. · European Journal of Pharmacology · 2002 · 509 citations

Medicine, Medicinal Chemistry, Pharmacology +15

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

Tetsuro Kikuchi, Katsura Tottori, Yasufumi Uwahodo et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 275 citations · Full text

Medicine, Neuroscience, Pharmacology +17